US 11,702,631 B2
Antigen receptors and uses thereof
Ralf Holger Voss, Ingelheim (DE); Ugur Sahin, Mainz (DE); Petra Oehm, Mainz (DE); Matthias Birtel, Mainz (DE); and Janina Caspar, Waldalgesheim (DE)
Assigned to TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH; and BIONTECH CELL & GENE THERAPIES GMBH
Appl. No. 16/493,618
Filed by BIONTECH CELL & GENE THERAPIES GMBH, Mainz (DE); and TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH, Mainz (DE)
PCT Filed Mar. 14, 2018, PCT No. PCT/EP2018/056399
§ 371(c)(1), (2) Date Sep. 12, 2019,
PCT Pub. No. WO2018/167151, PCT Pub. Date Sep. 20, 2018.
Claims priority of application No. PCT/EP2017/056086 (WO), filed on Mar. 15, 2017.
Prior Publication US 2020/0063101 A1, Feb. 27, 2020
Int. Cl. C07K 14/705 (2006.01); C07K 19/00 (2006.01); C12N 5/0783 (2010.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 15/90 (2006.01); A61K 38/00 (2006.01)
CPC C12N 5/0636 (2013.01) [C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/28 (2013.01); C12N 15/90 (2013.01); A61K 38/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/70 (2013.01)] 15 Claims
OG exemplary drawing
 
1. An antigen receptor, which receptor comprises a first peptide chain and a second peptide chain,
wherein:
(i) the first peptide chain comprises an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL), a variable region of a T cell receptor chain, and an immunoreceptor signal transmission domain, and
the second peptide chain comprises an immunoglobulin heavy chain variable domain (VH), an immunoglobulin light chain variable domain (VL), a variable region of a T cell receptor chain, and an immunoreceptor signal transmission domain, and
wherein the VH domain from the first peptide chain forms together with the VL domain from the second peptide chain a first antigen binding site, and
wherein the VL domain from the first peptide chain forms together with the VH domain from the second peptide chain a second antigen binding site; or
(ii) the first peptide chain comprises two immunoglobulin light chain variable domains (VL), a variable region of a T cell receptor chain, and an immunoreceptor signal transmission domain, and
the second peptide chain comprises two immunoglobulin heavy chain variable domains (VH), a variable region of a T cell receptor chain, and an immunoreceptor signal transmission domain, and
wherein a first VL domain from the first peptide chain forms a first antigen binding site together with a first VH domain from the second peptide chain, and
wherein a second VL domain from the first peptide chain forms a second antigen binding site together with a second VH domain from the second peptide chain.